O24™ Fibromyalgia Receives First-Ever NFA Official Seal of
Approval 
Swiss Medica Inc. announced the launch of its keenly anticipated O24™
Fibromyalgia pain reliever during a joint press announcement with the
National Fibromyalgia Association at the June National Association of
Chain Drug Stores Marketplace conference in New Orleans.
Patented, clinically tested, and all-natural, the O24™ Fibromyalgia is the first
product of its kind developed specifically to address the chronic pain
associated with fibromyalgia, and to be sold over-the-counter in retail
pharmacies. The palm-sized O24™ towelettes, which contain eucalyptus,
aloe vera, peppermint, rosemary, lemon, and orange oils, can be applied
to painful areas of the body to decrease pain.
As part of the launch, Swiss Medica also announced a strategic
partnership with the NFA. Executive Director Lynne Matallana spoke about
the challenge of living with fibromyalgia, and explained why O24™
Fibromyalgia pain reliever has become the first product to carry the
NFA's new official Seal of Approval on its packaging.
"Working with the National Fibromyalgia Association will provide
Swiss Medica with a unique opportunity to introduce our patented, safe,
effective and completely natural pain relief technology to people with
fibromyalgia," said Grant Johnson, President of Swiss Medica Inc. "It's
also the start of an on-going commitment to support the much-needed
services that the NFA provides to fibromyalgia sufferers."
As part of this strategic partnership, the non-profit NFA will
receive a percentage of the proceeds from the sale of O24™ Fibromyalgia.
This revenue will directly benefit people with FM by supporting the
programs and services of the NFA.
"The fibromyalgia community is desperate for safe, effective
treatment options to help reduce FM symptoms, including long-term
widespread muscle pain," said Matallana.
"Even though there are up to 11 million Americans suffering with FM,
there have been only a few products developed and clinically tested to
evaluate their effectiveness specifically for fibromyalgia pain. We are
pleased that Swiss Medica has not only developed such a product, but is
now committed to helping support patient service programs and future
research implemented by the NFA to directly benefit the FM community.
The NFA's partnership with Swiss Medica will be an incalculable benefit
to our 400,000 members."
Johnson also discussed the previously announced results of a recently
completed randomized double blind clinical trial that compared the O24™
Fibromyalgia pain reliever against a placebo on patients suffering
fibromyalgia. This double blind clinical trial was conducted earlier
this year at the University of Toronto's Sunnybrook & Women's Health
Sciences Centre.
The pilot study, conducted over a four-to-six week period, compared
the O24™ Fibromyalgia pain reliever against a placebo in patients
suffering with fibromyalgia. 68 (51%) used a placebo. The other 65 (49%)
used the O24™ Fibromyalgia product.
For participants who used O24™ Fibromyalgia, more than 90 percent of
the patients reported mild to markedly better improvement. More than
half reported moderately better or markedly better results using O24™
Fibromyalgia instead of the placebo.
National Fibromyalgia Association
2200 N. Glassell St., Suite A, Orange, Ca 92865
Phone: 714-921-0150 Fax: 714-921-6920
